Novartis and BeiGene have mutually agreed to axe their collaboration on a Phase III TIGIT inhibitor, marking another derailment in a field once thought to be the next immunotherapy breakthrough.
Novartis doled out $300 million to kick off their partnership for ociperlimab in 2021, and was willing to pay up to $700 million more if it had decided to pick up the development and commercialization rights in multiple countries before the end of this year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters